市場調查報告書
商品編碼
1554406
2024-2032 年日本生物製品市場報告(按來源、產品、疾病、製造和地區)Japan Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032 |
預計 2024 年至 2032 年日本生物製品市場規模的成長率 (CAGR) 為 6.10%。對精準醫療方法的需求不斷成長,對罕見疾病治療的日益關注,以及癌症、類風濕關節炎、多發性硬化症和慢性發炎等慢性和複雜疾病盛行率的上升,是推動市場發展的一些關鍵因素。
生物製劑包括多種藥物,包括單株抗體、疫苗、基因療法和細胞療法。它們源自活生物體或其成分,例如細胞、蛋白質、基因或組織。它們是透過生物技術方法生產的,與透過化學過程合成的傳統化學藥物不同。它們與體內的特定標靶相互作用以達到治療效果。它們以其高特異性和有效性而聞名,與傳統藥物相比,通常副作用更少。它們刺激免疫系統產生免疫反應,而不會引起疾病本身,有助於保護個體免受各種病毒和細菌的侵害。它們可以根據患者疾病的特定遺傳或分子特徵進行客製化,從而實現個人化治療方法。與傳統化學藥物相比,它們可以促進組織再生和傷口癒合,並且副作用更少。它們透過增強身體針對癌細胞的免疫反應來幫助治療某些類型的癌症。他們協助解決影響少數族群的罕見疾病和孤兒疾病。它們用於治療、預防或控制各種醫療狀況和疾病。隨著它們透過有效管理症狀和減緩疾病進展來改善患者的生活品質,日本對生物製劑的需求正在上升。
目前,癌症、類風濕性關節炎、多發性硬化症和慢性發炎等慢性和複雜疾病在個人中的盛行率不斷增加,這是促進日本市場成長的主要因素之一。此外,生物製劑的使用不斷增加,因為它們降低了住院頻率和嚴重程度,正在加強該國市場的成長。除此之外,對精準醫療方法不斷成長的需求也帶來了積極的市場前景。此外,患者對生物製劑益處的認知不斷提高,例如副作用更少、住院時間縮短和治療效果持久,這為日本的行業投資者提供了利潤豐厚的成長機會。與此一致的是,對治療癌症的免疫療法和單株抗體的需求不斷成長,正在對市場產生積極影響。此外,生物生產方法的創新有利於生物製劑的成本效益和高效生產,從而促進了市場的成長。除此之外,該國生物製劑臨床試驗數量的增加正在推動市場成長。此外,大眾對治療罕見疾病的日益關注正在推動市場成長。生物技術和基因組學的技術進步促進了新型生物製劑的發現和開發,這也支持了日本市場的成長。
IMARC Group提供了每個細分市場的主要趨勢的分析,以及 2024-2032 年國家層級的預測。我們的報告根據來源、產品、疾病和製造對市場進行了分類。
該報告根據來源提供了詳細的市場細分和分析。這包括微生物、哺乳動物等。
報告還提供了基於該產品的詳細市場細分和分析。這包括單株抗體、疫苗、重組蛋白、反義、RNAi 和分子療法等。
該報告根據疾病提供了詳細的市場細分和分析。這包括腫瘤學、免疫學疾病、心血管疾病、血液學疾病等。
報告還提供了基於製造的詳細市場細分和分析。這包括外包和內部。
該報告還對所有主要區域市場進行了全面分析,包括關東地區、關西/近畿地區、中部/中部地區、九州沖繩地區、東北地區、中國地區、北海道地區和四國地區。
市場研究報告也對競爭格局進行了全面分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外,也提供了所有主要公司的詳細資料。
此處未提供公司名稱,因為這是目錄範例。報告中提供了完整的清單。
Japan biologics market size is projected to exhibit a growth rate (CAGR) of 6.10% during 2024-2032. The growing demand for precision medicine approaches, increasing focus on treating rare diseases, and rising prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, represent some of the key factors driving the market.
Biologics comprise a wide range of pharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. They are derived from living organisms or their components, such as cells, proteins, genes, or tissues. They are produced through biotechnological methods, unlike traditional chemical-based drugs that are synthesized through chemical processes. They interact with specific targets in the body to achieve therapeutic effects. They are known for their high specificity and efficacy, often resulting in fewer side effects compared to conventional drugs. They stimulate the immune system to produce an immune response without causing the disease itself, helping to protect individuals from various viruses and bacteria. They can be tailored to specific genetic or molecular characteristics of disease of patient, enabling personalized treatment approaches. They promote tissue regeneration and wound healing and have fewer side-effects as compared to traditional chemical drugs. They aid in treating certain types of cancer by enhancing the immune response of the body against cancer cells. They assist in addressing rare diseases and orphan diseases that affect a small population. They are used to treat, prevent, or manage various medical conditions and diseases. As they improve the quality of life for patients by effectively managing symptoms and slowing disease progression, the demand for biologics is rising in Japan.
At present, the increasing prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, among individuals represents one of the major factors contributing to the market growth in Japan. Moreover, the rising usage of biologics, as they reduce the frequency and severity of hospitalizations, is strengthening the growth of the market in the country. Apart from this, the escalating demand for precision medicine approaches is offering a positive market outlook. Additionally, the increasing awareness among patients about the benefits of biologics, such as fewer side effects, reduced hospital stays, and long-lasting therapeutic effects, is providing lucrative growth opportunities to industry investors in Japan. In line with this, the growing demand for immunotherapies and monoclonal antibodies for treating cancer is influencing the market positively. In addition, innovations in bioproduction methods benefit in cost-effective and efficient production of biologics, which is bolstering the growth of the market. Besides this, the rising number of clinical trials for biologics in the country is propelling the market growth. Furthermore, the increasing focus on treating rare diseases among the masses is impelling the market growth. The technological advancement in biotechnology and genomics enhances the discovery and development of novel biologics, which is also supporting the market growth in Japan.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on source, product, disease, and manufacturing.
The report has provided a detailed breakup and analysis of the market based on the source. This includes microbial, mammalian, and others.
A detailed breakup and analysis of the market based on the product have also been provided in the report. This includes monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi and molecular therapy, and others.
The report has provided a detailed breakup and analysis of the market based on the disease. This includes oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others.
A detailed breakup and analysis of the market based on the manufacturing have also been provided in the report. This includes outsourced and in-house.
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Company names have not been provided here as this is a sample TOC. The complete list is provided in the report.